Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-06-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
北京德恒（昆明）律师事务所关于公司2016年股权激励计划所涉限制性股票授予相关事宜的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and compliance of a company's 2016 equity incentive plan involving restricted stock grants. It references relevant laws, regulatory approvals, company board meetings, and details about stock repurchases and grants. The document is a legal opinion and compliance confirmation related to a stock incentive plan, not a financial report, earnings release, or regulatory announcement. It does not contain financial statements or earnings data, nor is it a proxy solicitation or voting result announcement. It is a specialized legal opinion on a corporate equity incentive plan. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2016-06-20 Chinese
八届六次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on specific company matters related to stock incentive repurchase and restricted stock grant dates. The document is short (534 characters) and focuses on board/supervisory decisions rather than financial results or reports. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2016-06-20 Chinese
2016年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is a list of recipients and details of a 2016 restricted stock incentive plan for a company, including names, positions, and stock quantities granted. It is a disclosure related to share-based compensation for executives and directors. This type of document typically falls under Remuneration Information, as it details compensation in the form of stock incentives for top executives and directors. The document is short and specific to stock incentives, not a full report or announcement of voting results or capital changes. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2016-06-20 Chinese
关于独立董事公开征集投票权公告的更正公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a correction announcement regarding a previous announcement about the solicitation of voting rights by independent directors for a company's extraordinary general meeting (2016 third extraordinary shareholders meeting). It includes corrected agenda items for shareholder voting and an attached proxy authorization form for voting rights. The content focuses on voting rights solicitation and proxy authorization for a specific shareholders meeting, not the meeting materials themselves or the voting results. It is not a full report, financial statement, or earnings release. The document is an announcement related to shareholder voting rights solicitation and proxy authorization, which fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). However, since it is a correction to a voting rights solicitation announcement and includes the proxy form, it is more precisely a voting rights announcement rather than voting results. Therefore, the best classification is DVA (Declaration of Voting Results & Voting Rights Announcements). The document length is 2552 characters, which is short but contains substantive content about voting rights solicitation and proxy authorization, not just a brief notice or report publication announcement.
2016-06-15 Chinese
2016年第三次临时股东大会会议资料（更正）
AGM Information Classification · 100% confidence The document is titled as materials for the 2016 third extraordinary general meeting of shareholders of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and multiple proposals to be voted on by shareholders, including amendments to the company charter and a restricted stock incentive plan. The content is focused on the meeting itself, including procedural rules, agenda items, and explanations of proposals, which are typical of materials provided to shareholders before or during a general meeting. There is no financial data or earnings information, nor is it a transcript or announcement of results. The document is not a report publication announcement but the actual meeting materials. Therefore, this document fits the category of AGM Information (AGM-R).
2016-06-15 Chinese
关于2016年第三次临时股东大会通知的更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding the notice for the 2016 third extraordinary shareholders' meeting of Kunming Pharmaceutical Group Co., Ltd. It details corrections to the agenda items for the meeting, voting procedures, and includes an authorization proxy form for shareholders to vote. The content focuses on meeting logistics, agenda corrections, and proxy voting instructions rather than the meeting materials themselves or the voting results. It is not a full report like an Annual Report or Interim Report, nor is it a voting results announcement. It is a notice correcting and supplementing the original shareholders' meeting notice, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2016-06-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.